Active	Status	Sponsor type	Region	Phase	Filter
6 Active 4 Inactive 10 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Noordegraaf, Anton Vonk
IMPAHCT, NCT05036135 / 2021-001910-13: A Study of AV-101 (Dry Powder Inhaled Imatinib) in Patients With Pulmonary Arterial Hypertension (PAH)	Terminated	2/3	202	Europe, Canada, US, RoW	AV-101, Placebo	Aerovate Therapeutics, Aerovate Therapeutics, Inc.	Pulmonary Arterial Hypertension	08/24	08/24
Vizza, Dario
IMPAHCT-FUL, NCT05557942 / 2021-006864-25: Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial - Follow Up Long Term Extension	Terminated	3	186	Europe, Canada, US, RoW	AV-101	Aerovate Therapeutics, Aerovate Therapeutics Inc	Pulmonary Arterial Hypertension	08/24	08/24
IMPAHCT, NCT05036135 / 2021-001910-13: A Study of AV-101 (Dry Powder Inhaled Imatinib) in Patients With Pulmonary Arterial Hypertension (PAH)	Terminated	2/3	202	Europe, Canada, US, RoW	AV-101, Placebo	Aerovate Therapeutics, Aerovate Therapeutics, Inc.	Pulmonary Arterial Hypertension	08/24	08/24